Sonoma Pharmaceuticals (SNOA) Total Liabilities (2011 - 2026)

Sonoma Pharmaceuticals' Total Liabilities history runs 16 years deep, the most recent figure standing at $10.9 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 17.05% year-over-year to $10.9 million in Q1 2026; TTM through Mar 2026 was $10.9 million, a 17.05% increase from a year earlier, with the FY2026 full-year figure at $10.9 million, up 17.05% from the prior year.
• Total Liabilities climbed to $10.9 million in Q1 2026 per SNOA's latest filing, from $10.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $10.9 million in Q1 2026 and bottomed at $7.9 million in Q4 2023.
• The 5-year median for Total Liabilities is $8.7 million (2024), against an average of $9.0 million.
• Across the five-year window, Total Liabilities fell 18.66% in 2023 and climbed 21.15% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $8.4 million in 2022, then retreated by 5.29% to $7.9 million in 2023, then climbed by 11.0% to $8.8 million in 2024, then grew by 15.83% to $10.2 million in 2025, then rose by 6.61% to $10.9 million in 2026.
• Per Business Quant, the three latest SNOA Total Liabilities figures stand at $10.9 million (Q1 2026), $10.2 million (Q4 2025), and $10.1 million (Q3 2025).